Post Analytic Treatment Interruption Study

Safety and Virologic Outcomes After Analytic Treatment Interruption in Thai Patients Who Initiated Antiretroviral Therapy During Early Acute HIV Infection

This exploratory study is designed to ensure the safety of HIV-infected volunteers who complete research protocols that include an analytic treatment interruption (ATI). This is a prospective cohort study of volunteers who were diagnosed with HIV during early acute HIV infection, treated with antiretroviral therapy (ART) and subsequently enrolled in a clinical study that included ATI. After completion of study participation that involves ATI, participants will be recruited into this study for continued clinical and laboratory monitoring.

Study Overview

• Status: Recruiting
• Conditions: HIV

Detailed Description

This exploratory study is designed to ensure the safety of HIV-infected volunteers who complete research protocols that include an analytic treatment interruption (ATI). This is a prospective cohort study of volunteers who were diagnosed with HIV during early acute HIV infection, treated with antiretroviral therapy (ART) and subsequently enrolled in a clinical study that included ATI. After completion of study participation that involves ATI, participants will be recruited into this study for continued clinical and laboratory monitoring. Participants without any indication for resumption of ART and who desire to remain off ART at the time of entry into this study will be monitored closely for HIV viremia and other pre-defined criteria for ART resumption. Participants with any indication for ART at the time of enrollment into this protocol, including patient preference for resumption of ART, will be monitored closely for virologic and immunologic response to ART.

Clinical study visits will take place at the Thai Red Cross AIDS Research Centre, and the optional procedures may occur at the King Chulalongkorn Memorial Hospital. Required laboratory studies that are outlined in this protocol will occur in lieu of those described in the RV 254 protocol. Volunteers may provide separate informed consent for optional procedures to include collection of genital secretions, colon biopsy, inguinal lymph node biopsy, cerebrospinal fluid (CSF) collection via lumbar puncture, and brain Magnetic Resonance Imaging (MRI)/Magnetic Resonance Spectroscopy (MRS)/Diffusion Tensor Imaging (DTI). With separate informed consent, willing participants will undergo archival of peripheral blood mononuclear cells and plasma specimens for research purposes.

This study will enroll volunteers aged 18 years and older who have completed clinical studies that include ATI in Bangkok, Thailand. Enrollment in this study will be concurrent with completion of the study with ATI. Participants will fall broadly into one of two categories: those on ART and those not on ART at the completion of the prior study protocol.

The ongoing parent study, RV 254 (SEARCH 010, WRAIR 1494), enrolls participants with documented acute HIV infection at the Thai Red Cross AIDS Research Center in Bangkok, Thailand. Participants in the cohort are primarily men who have sex with men, but also include men and women with other HIV acquisition risk factors as well as various ages, incomes, and education levels. All participants in RV 254 are offered ART at the time of enrollment through a separately funded protocol. Participants in this substudy will remain co-enrolled in RV254/SEARCH010, but will follow the schedule of event (SOE) for this sub-study in lieu of the parent study SOE.

• Study Type: Observational
• Enrollment (Estimated): 50

Contacts and Locations

• Study Contact: Name: Nittaya Phanuphak, MD, PhD; Email: nittaya.p@ihri.org
• Study Contact Backup: Name: Nitiya Chomchey, PhD; Email: nitiya.c@searchthailand.org

Study Locations

• Thailand
  • Bangkok, Thailand, 10330
    • Recruiting
    • SEARCH
    • Contact: Nittaya Phanuphak, MD, PhD; Phone Number: +6622542566; Email: nittaya.p@trcarc.org
    • Contact: Nitiya Chomchey, MSc; Phone Number: 111 +6622542566; Email: nitiya.c@searchthailand.org

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

This study will recruit adults aged 18 years and older at the time of documented acute HIV infection (Fiebig stage I to V) and initiation of ART in Bangkok, Thailand, who have completed clinical research protocols that included analytic treatment interruption (ATI).

Description

Inclusion Criteria:

• Man or woman aged ≥18 years.
• Enrolled in RV254 study.
• Completed clinical research protocol that included ATI within one month of enrollment in this protocol.
• Able and willing to provide written informed consent or, in the case of illiteracy, witnessed verbal informed consent with documentation of a thumbprint in lieu of a signature.
• Able to participate in study visits for up to 144 weeks.
• Willing to have photo or fingerprint taken for identification purposes.
• Female-specific criteria: Agrees not to become pregnant while not receiving ART. If a woman is sexually active and has no history of hysterectomy or tubal ligation or menopause, she must agree to engage in abstinence, use a prescription birth control method or use a barrier birth control method while not receiving ART.

Exclusion Criteria:

• History of a medical or psychiatric condition that, in the opinion of investigator, would jeopardize the safety or rights of the subject, such as a condition that would interfere with or serve as a contraindication to adherence to the study protocol or ability to give informed consent.

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort
volunteer who completion of a recent ATI

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Antiretroviral therapy (ART) resumption for any reason	96 weeks

Secondary Outcome Measures

Outcome Measure	Time Frame
Viral suppression after ART resumption	48 weeks
Time to viral rebound, from cessation of ART	96 weeks
Level of viral rebound after cessation of ART	96 weeks
Detectable HIV RNA via single copy assay at various timepoints, such as weeks 48 and 96 off ART, as compared to baseline prior to ATI	48 and 96 weeks

Collaborators and Investigators

• Sponsor: SEARCH Research Foundation
• Collaborators: US Military HIV Research Program
• Investigators: Principal Investigator: Nittaya Phanuphak, MD, PhD, SEARCH Research Foundation

Study record dates

Study Major Dates

• Study Start: March 1, 2016
• Primary Completion (Estimated): March 1, 2031
• Study Completion (Estimated): March 1, 2031

Study Registration Dates

• First Submitted: April 25, 2016
• First Submitted That Met QC Criteria: May 1, 2016
• First Posted (Estimated): May 4, 2016

Study Record Updates

• Last Update Posted (Estimated): November 22, 2023
• Last Update Submitted That Met QC Criteria: November 20, 2023
• Last Verified: November 1, 2023

More Information

Terms related to this study

• Other Study ID Numbers: SEARCH 025/RV412

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED